US House Financial Services Committee passes Small Business Lending Fund Act of 2010; seen as helping biotech which would get $1 billion

24 May 2010

The USA's House of Representatives Financial Services Committee passed legislation including two important Administration proposals - a Small Business Lending Fund that provides incentives for smaller banks to make new loans, and a State Small Business Credit Initiative that would spur over $20 billion in new lending through innovative state-based programs at a time when states are being forced to cut back on them due to budget shortfalls.

Within this, the biotechnology sector is set to be eligible for around $1 billion. Details have yet to be announced, but the funds will come in the form of tax credits, or as a grant for the many unprofitable companies, covering 50% of project development costs in 2009 and 2010 for companies with fewer than 250 workers.

'Small businesses are the backbone of the American economy, and where most new jobs begin,' commented US President Barack Obama, expressing pleasure at the passage of the legislation. 'In March, I signed into law a jobs bill that provides tax cuts to small businesses that hire new workers, and have proposed eliminating capital gains taxes on small business investments and new tax breaks for all businesses to invest in new plants and equipment,' he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology